In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study) | Zendy

Andrew Walkty | Zendy; Melanie DeCorby | Zendy; Philippe LagacéWiens | Zendy; James A. Karlowsky | Zendy; D. J. Hoban | Zendy; George G. Zhanel | Zendy

Open Access

In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)

Author(s) -

Andrew Walkty,

Melanie DeCorby,

Philippe LagacéWiens,

James A. Karlowsky,

D. J. Hoban,

George G. Zhanel

Publication year - 2011

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01696-10

Subject(s) - ceftazidime , pseudomonas aeruginosa , broth microdilution , microbiology and biotechnology , ceftazidime/avibactam , medicine , biology , minimum inhibitory concentration , chemistry , antibiotics , bacteria , genetics

The in vitro activity of ceftazidime in combination with NXL104 versus 470 Pseudomonas aeruginosa clinical isolates was evaluated using Clinical and Laboratory Standards Institute (CLSI) broth microdilution methods. Ceftazidime had MIC₉₀s of 8 μg/ml and 32 μg/ml in the presence and absence of NXL104, respectively. Of 25 multidrug-resistant P. aeruginosa isolates, the percentages with a ceftazidime MIC of ≤8 μg/ml with and without NXL104 were 60% and 4%, respectively. These data suggest that the ceftazidime-NXL104 combination may prove useful for treating many P. aeruginosa infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research